Last reviewed · How we verify
Biomarker-eligible patients with unresectable or metastatic pheochromocytoma
Approved treatments
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Biomarker-eligible patients with unresectable or metastatic pheochromocytoma patent landscape — cliff calendar, originator estates, attackable patents
- Biomarker-eligible patients with unresectable or metastatic pheochromocytoma treatment landscape brief
- Biomarker-eligible patients with unresectable or metastatic pheochromocytoma treatment updates RSS
Frequently asked questions about Biomarker-eligible patients with unresectable or metastatic pheochromocytoma
What drugs treat Biomarker-eligible patients with unresectable or metastatic pheochromocytoma?
Tracked treatments include PF-07220060 + PF-07104091 combination dose escalation.
What is the treatment for Biomarker-eligible patients with unresectable or metastatic pheochromocytoma?
Standard treatment for Biomarker-eligible patients with unresectable or metastatic pheochromocytoma includes PF-07220060 + PF-07104091 combination dose escalation. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Biomarker-eligible patients with unresectable or metastatic pheochromocytoma patent cliff · Biomarker-eligible patients with unresectable or metastatic pheochromocytoma CI report
- Treatment: PF-07220060 + PF-07104091 combination dose escalation · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing